India Pharma Outlook Team | Tuesday, 10 November 2026
CDMO growth is becoming a central focus for BDR Pharma as it expands its pharmaceutical manufacturing capabilities and international business opportunities.
The company has announced its acquisition of a controlling stake in Acme Formulations' oral formulations business from existing shareholders led by PAG.
The transaction strengthens BDR Pharma's contract development and manufacturing organization (CDMO) platform by adding specialized formulation capabilities and complementary therapeutic expertise.
This acquisition marks another important step in BDR Pharma's expansion strategy, with potential implications for its manufacturing scale, product commercialization and long-term global growth.
BDR Pharma's acquisition covers Acme Formulations' oral solid formulations business and its associated operations. Founded in 2005, Acme provides contract development and manufacturing services across several pharmaceutical categories and exports to more than 40 countries.
The acquisition brings complementary capabilities in:
These capabilities strengthen BDR Pharma's existing portfolio without significant therapeutic overlap, allowing the company to broaden its specialized manufacturing offerings.
“We have been on a strong growth trajectory driven by strategic investments, and Acme will further strengthen our CDMO platform and add differentiated capabilities to expand our global presence”, said Dharmesh Shah, Chairman and Managing Director, BDR Pharma.
Also Read: Sterile Injectable CDMO in India: Manufacturing, Fill-Finish, Technology & Regulatory Guide 2026
Acme's manufacturing infrastructure offers BDR Pharma opportunities to connect its formulation capabilities with international commercialization plans. Its USFDA-approved manufacturing facilities could support the commercialization of BDR Pharma's recently acquired Abbreviated New Drug Application (ANDA) portfolio in the US market.
This combination could strengthen BDR Pharma across three important areas:
The transaction also aligns with BDR Pharma's broader expansion strategy, which includes a planned Rs 700 crore investment in organic and inorganic growth. Meanwhile, PAG and Acme founder Viral Shah will retain ownership of Immacule, Acme's sterile injectable business, following the transaction.
BDR Pharma's acquisition therefore represents more than a manufacturing expansion. Combining specialized formulations with its product portfolio could strengthen its CDMO growth ambitions, while execution and commercialization will determine how effectively the company translates these capabilities into international opportunities.
.jpg)
